CleanSpark and HIVE Digital Technologies sit in the same competitive space. Both started as bitcoin miners and are now shifting their energy assets toward AI and HPC data centers. This common transition makes them a useful pair for comparison, as their results will hinge more on landing and financing long-term computing deals than on bitcoin prices alone. For investors looking at digital infrastructure and crypto-related stocks, the differences in scale, contracted revenue, balance sheet strength, and momentum matter when weighing relative performance.
CleanSpark, based in Henderson, Nevada, has moved quickly into AI and HPC data center development on top of its bitcoin mining operations. Its main project is a campus in Sandersville, Georgia, backed by a roughly $6.6 billion, 20-year lease with a Meta subsidiary. In recent weeks the company closed $2.276 billion in senior secured notes, confirming the Sandersville build-out is fully funded, and shifted from monthly to quarterly operational reporting as the data center side expands. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Even with this progress, the stock has remained under pressure. Mining margins weakened as bitcoin prices declined, and quarterly revenue fell year over year while the company posted a sizable net loss that included non-cash charges. Shares have hovered near their 52-week low, with a beta above 3.0 highlighting the volatility. Sentiment is divided between optimism over the AI contract pipeline and caution around rising debt and execution risks.
HIVE Digital Technologies runs green-energy data centers in Canada, Sweden, Paraguay, and Bermuda. It follows a dual strategy of bitcoin mining and GPU cloud services through its BUZZ HPC unit. In recent months BUZZ HPC signed a five-year, roughly $350 million GPU cloud agreement and an earlier three-year, approximately $220 million contract, pushing its annualized revenue run rate to about $180 million with a target of $200 million in annual recurring revenue by year-end.
Still, the share price has not matched the contract momentum. HIVE continues to report negative GAAP earnings, and growth remains capital-intensive, partly financed through zero-coupon convertible notes and additional debt. Management has noted what it sees as a geographic discount, suggesting investors value its Canadian AI assets lower than U.S. peers. Shares have traded near the lower end of their 52-week range amid dilution concerns and sector-wide volatility.
The clearest differences appear in scale and contract certainty. CleanSpark has a signed, long-term lease with a large, investment-grade counterparty and a larger liquidity buffer, which anchors its AI transition more firmly. HIVE has already built recurring GPU cloud revenue through multiple multi-year deals, yet its revenue base is smaller, its funding relies more on convertibles and debt, and its assets face a perceived geographic discount.
Both companies share risks around bitcoin price sensitivity, heavy capital spending, and potential dilution. CleanSpark’s near-term focus is on execution and permitting for its Texas pipeline, while HIVE’s centers on funding gaps and ongoing GAAP losses. Sector exposure is comparable, but CleanSpark’s larger contracted backlog and balance sheet provide relatively more stability, even though both stocks remain high-beta and well below their peaks.
Based on factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron’s AI currently leans toward CLSK (CleanSpark). The signed Meta lease, fully funded flagship project, larger liquidity position, and broader analyst coverage point to a more stable and visible path through the sector transition than HIVE’s smaller, more leverage-dependent profile. This is a probabilistic view of relative strength rather than a firm prediction, and both names carry meaningful volatility and execution risk ahead.
I’ve found Tickeron’s AI Trading Bots helpful for reviewing how different automated strategies are handling names like these in real time. The platform offers hundreds of bots with varied styles, timeframes, and performance data, letting users match tools to their own objectives and risk tolerance. It provides a practical way to see AI-driven approaches applied to volatile sectors without needing to build models from scratch.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HIVE moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 34 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIVE as a result. In 69 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 10-day moving average for HIVE crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for HIVE moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIVE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for HIVE entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for HIVE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where HIVE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for HIVE just turned positive on October 29, 2026. Looking at past instances where HIVE's MACD turned positive, the stock continued to rise in 30 of 38 cases over the following month. The odds of a continued upward trend are 79%.
Following a +11.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIVE advanced for three days, in 213 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.972) is normal, around the industry mean (3.108). P/E Ratio (9.174) is within average values for comparable stocks, (6.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.809). Dividend Yield (0.000) settles around the average of (7.800) among similar stocks. P/S Ratio (2.169) is also within normal values, averaging (16.899).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. HIVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of cloud networking and enterprise Wi-Fi solution
Industry InvestmentBanksBrokers